Next to its detection in CNS tissue sections from patients with MS [65], IFNγ could be attributed to disease progression as its expression has been shown to be increased in the serum of MS patients with ongoing progression compared to patients without progression [25, 26]. The gene discussed is IFNG; the disease is myeloid sarcoma.